These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Kizaki M; Koeffler HP Semin Oncol; 1992 Feb; 19(1):95-105. PubMed ID: 1371019 [No Abstract] [Full Text] [Related]
3. Aspects on the clinical use of hematopoietic growth factors in myelodysplastic syndromes. Hast R; Eriksson M; Jakovleva K Pol Arch Med Wewn; 1998 Feb; 99(2):144-9. PubMed ID: 9686516 [No Abstract] [Full Text] [Related]
4. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study. Wu L; Li X; Chang C; Xu F; He Q; Wu D; Zhang Z; Su J; Zhou L; Song L; Chao X; Zhao Y Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697 [TBL] [Abstract][Full Text] [Related]
6. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants. Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258 [TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes. Xu WL; Jin J; Qian WB Chin Med J (Engl); 2010 Jan; 123(1):108-10. PubMed ID: 20137586 [No Abstract] [Full Text] [Related]
8. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA]. Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588 [TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772 [TBL] [Abstract][Full Text] [Related]
10. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine. Wu L; Li X; Xu F; Chang C; He Q; Zhang Z; Zhang Y Ann Hematol; 2012 Oct; 91(10):1547-54. PubMed ID: 22580751 [TBL] [Abstract][Full Text] [Related]
11. [What are the treatment possibilities for myelodysplastic syndrome?]. von Wichert P Internist (Berl); 1995 Jan; 36(1):74-5. PubMed ID: 7883535 [No Abstract] [Full Text] [Related]
12. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Ganser A; Hoelzer D Semin Hematol; 1996 Jul; 33(3):186-95. PubMed ID: 8819229 [No Abstract] [Full Text] [Related]
13. New approaches in the treatment of MDS: an overview of current trials. Jehn U Acta Haematol Pol; 1990; 21(2):129-38. PubMed ID: 1719727 [No Abstract] [Full Text] [Related]